Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Ian Flinn, MD
Advertisement
Articles by Ian Flinn, MD
Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).
Advertisement
Latest Updated Articles
Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin LymphomaPublished: July 11th 2018 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial
2
Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation
3
Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025
4
